A Prospective Controlled Trial to Evaluate Safety and Efficacy of in vitro Expanded Recipient Regulatory T Cell Therapy and Tocilizumab Together With Donor Bone Marrow Infusion in HLA-Mismatched Living Donor Kidney Transplant Recipients (Trex001)

Frontiers in Medicine

Peter Kalhs¹  Michael Wolzt²  Nina Worel³  Rainer Oberbauer⁴  Gabriela Berlakovich⁵  Georg Heinze⁶  Thomas Wekerle⁷  Thomas Lion⁸  Matthias Edinger⁹ 

[1] Bone Marrow Transplant Unit, Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria;Clinical Trials Coordination Centre, Medical University of Vienna, Vienna, Austria;Department of Blood Group Serology and Transfusion Medicine, Medical University of Vienna, Vienna, Austria;Division of Nephrology and Dialysis, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria;Division of Transplantation, Department of Surgery, Medical University of Vienna, Vienna, Austria;Section for Clinical Biometrics, Center for Medical Statistics, Informatics and Intelligent Systems, Medical University of Vienna, Vienna, Austria;Section of Transplantation Immunology, Division of Transplantation, Department of Surgery, Medical University of Vienna, Vienna, Austria;St. Anna Children's Cancer Research Institute, Vienna, Austria;Ludwig Boltzmann Institute for Hematology & Oncology, Medical University of Vienna, Vienna, Austria;Labdia Labordiagnostik GmbH, Vienna, Austria;Department of Pediatrics, Medical University of Vienna, Vienna, Austria;University Hospital Regensburg, Department of Internal Medicine III & Regensburg Center for Interventional Immunology (RCI), Regensburg, Germany;

关键词: kidney transplantation;    cell therapy;    regulatory T cells;    chimerism;    tolerance;    bone marrow;    belatacept;    tocilizumab;   

DOI  :  10.3389/fmed.2020.634260

来源: Frontiers

【 授权许可】

CC BY